secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harmony Biosciences Holdings, Inc. (HRMY)
CIK:        0001802665
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001558370-23-014932
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harmony Biosciences to acquire Zynerba for $1.1059 cash + CVR up to $2.5444 per share
--------------------------------------------------------------------------------

- Total potential consideration up to ~$3.65/share: $1.1059 cash plus a CVR worth up to $2.5444 upon milestones.
- CVR milestones include Zygel pivotal study completion, NDA approvals, and sales thresholds aggregating up to $140M.
- Zynerba directors/officers holding ~6.9% of shares have agreed to tender their shares in support.
- Tender offer minimum condition: at least one share more than 50% of outstanding Zynerba shares must be tendered.
- Termination fee of $4.5M payable by Zynerba if it accepts a superior proposal in certain circumstances.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802665/000155837023014932/0001558370-23-014932-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802665/000155837023014932/hrmy-20230814x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-014932

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer